The use of diabetes drugs in Canadian drug plans = Utilisation des médicaments contre le dibète dans les régimes publics d'assurance-médicaments du Canada. : H82-23/2016-PDF

"The cost of diabetes treatment has been rapidly increasing in Canada in recent years. While the growing prevalence of the disease is a contributing factor, more expensive treatments have been a major cost driver, especially given the uptake in new, higher-cost drugs. This study analyzes these issues from the perspective of Canadian public drug plans, and provides insight into the actual use of the newer and higher-cost diabetes drugs and their associated cost pressures. Results are presented for all public drug plans participating in NPDUIS: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and Health Canada’s Non-Insured Health Benefits drug plan. This analysis will support policy decision makers and the health technology assessment community in determining the future impact of diabetes treatments on their plans."

Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.833914&sl=1

• Format MARC XML
• Format MARC HTML

Demander des formats alternatifs